In-depth exploration of Trp metabolism has led to novel therapeutic strategies, including inhibiting key enzymes such as indoleamine 2,3-dioxygenase (IDO) and Trp 2,3-dioxygenase (TDO) to block Trp utilization, thereby enhancing immune response and inhibiting tumor growth. Here, IDO1 is linked to neoplasm.